CNS Pharmaceuticals Files 8-K
Ticker: CNSP · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, SEC
TL;DR
CNS Pharmaceuticals filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On April 9, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates CNS Pharmaceuticals is providing updated information to the SEC, which could include financial details or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high risk.
Key Numbers
- 001-39126 — SEC File Number (Identifier for the company's filings)
- 822318545 — IRS Number (Company's Employer Identification Number)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The provided excerpt states that 'Financial Statements and Exhibits' are included, but does not list the specific documents.
What is the primary purpose of the Regulation FD Disclosure mentioned in the filing?
Regulation FD (Fair Disclosure) aims to prevent selective disclosure of material nonpublic information by public companies.
When was the earliest event reported in this 8-K filing?
The earliest event reported is April 9, 2024.
What is the business address of CNS Pharmaceuticals, Inc.?
The business address is 2100 West Loop South, Suite 900, Houston, Texas 77027.
What is the state of incorporation for CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals, Inc. is incorporated in Nevada.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-04-12 18:37:47
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
Filing Documents
- cns_8k.htm (8-K) — 28KB
- cns_ex9901.htm (EX-99.1) — 28KB
- image_020.jpg (GRAPHIC) — 139KB
- image_021.jpg (GRAPHIC) — 229KB
- image_022.jpg (GRAPHIC) — 172KB
- image_023.jpg (GRAPHIC) — 117KB
- image_024.jpg (GRAPHIC) — 162KB
- image_025.jpg (GRAPHIC) — 177KB
- image_027.jpg (GRAPHIC) — 156KB
- image_028.jpg (GRAPHIC) — 170KB
- image_029.jpg (GRAPHIC) — 136KB
- image_030.jpg (GRAPHIC) — 169KB
- image_031.jpg (GRAPHIC) — 158KB
- image_032.jpg (GRAPHIC) — 235KB
- image_033.jpg (GRAPHIC) — 195KB
- image_034.jpg (GRAPHIC) — 235KB
- image_035.jpg (GRAPHIC) — 165KB
- image_036.jpg (GRAPHIC) — 172KB
- image_037.jpg (GRAPHIC) — 117KB
- image_038.jpg (GRAPHIC) — 111KB
- image_040.jpg (GRAPHIC) — 120KB
- 0001683168-24-002359.txt ( ) — 4560KB
- cnsp-20240409.xsd (EX-101.SCH) — 3KB
- cnsp-20240409_lab.xml (EX-101.LAB) — 33KB
- cnsp-20240409_pre.xml (EX-101.PRE) — 22KB
- cns_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Representatives of CNS Pharmaceuticals, Inc. (the "Company") will use the presentation set forth as Exhibit 99.1 herein in connection with various meetings from time to time with the investment community. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 CNS Pharmaceuticals, Inc. Investor Presentation – April 2024 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: April 12, 2024 3